EASD 2025 15 - 19 September 2025

Improved treatment satisfaction with once-weekly IcoSema vs daily basal-bolus therapy in adults with type 2 diabetes inadequately controlled on daily basal insulin (COMBINE 3)

Authors :

Paolo Fiorina¹; Malik Benamar²; Sin Gon Kim³; Raluca Maltesen⁴; Siri Vinther²; Liming Chen⁵

Affiliations

View Details Hide Details

Keywords

Diabetes

Congress short oral presentation

Insulin

IcoSema (Icodec Semaglutide)

PHASE 3 (RCT)

Are you a healthcare professional?